The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other safe stocks to buy for the long term in 2025. The US stock market is often ...

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.

So we wouldn't blame long term Bristol-Myers Squibb Company (NYSE:BMY) shareholders for doubting their decision to hold, with the stock down 14% over a half decade. So let's have a look and see if ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $73.00. Discover outperforming stocks and invest ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Monday, January 13, 2025. The company’s presentation and ...